NCT00759109View on ClinicalTrials.gov

Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Carcinoma, Hepatocellular
Interventions
BIOLOGICAL

Peginterferon alfa-2b

Peginterferon alfa-2b, 50 μg, weekly, SC, for a period of 3 years.

OTHER

Observation (no treatment)

No treatment was given to participants enrolled in the control arm (Arm B).

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00759109 - Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085) | Biotech Hunter | Biotech Hunter